Investigators Have Uncovered Global Trends in Risk Factors Linked to Lung Cancer Mortality
Recent statistics showing reductions in lung cancer–related mortality may not address trends linked to tobacco use, air pollution, and asbestos exposure.
Related Articles
Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma
In a phase II trial (Alliance A091802) reported in the Journal of Clinical Oncology, Zandberg et al investigated the survival benefit of adding cetuximab to…
Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment
In this installment of The ASCO Post’s Living a Full Life series, Stephen R. Grobmyer, MD, FACS, speaks about his clinical and research career in…
Revumenib in Triplet Regimen Under Study in Newly Diagnosed AML With NPM1/KMT2A Alterations
A new combination of azacitidine, venetoclax, and revumenib demonstrated high rates of complete response and clinical activity in older adults with newly diagnosed acute myeloid…
FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable, Locally Advanced Head and Neck Cancer
The FDA approved pembrolizumab (Keytruda) for adults with resectable, locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [combined positive score ≥…
Elinzanetant for Vasomotor Symptoms From Endocrine Therapy for Breast Cancer
In a phase III trial (OASIS-4) reported at the 2025 Annual ASCO Meeting and in the New England Journal of Medicine, Cardoso et al attempted…
Tumor Treating Fields Extend OS for Patients With Locally Advanced Pancreatic Cancer
The addition of tumor treating fields to first-line chemotherapy can extend overall survival without increasing systemic toxicity among patients with locally advanced pancreatic cancer, according…
Alicia K. Morgans, MD, MPH, FASCO, on How Does Androgen Receptor Inhibition Affect Quality of Life?
Alicia K. Morgans, MD, MPH, FASCO, of Dana-Farber Cancer Institute, discusses health-related quality-of-life data from the phase III ARAN OTE trial, which evaluated the androgen…
Adjuvant Cemiplimab in High-Risk Cutaneous Squamous Cell Carcinoma
In a phase III trial (C-POST) reported at the 2025 ASCO Annual Meeting and in The New England Journal of Medicine, Rischin et al compared…
Mark Cuban Does It Again: Reshuffling the Deck of Front-Line CML Therapy
With the currently available BCR::ABL1 tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has transformed from an invariably fatal disorder (10-year overall survival < 10%) to…
Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN
A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a…
